All In MedTech

FDA Clearance Tracker · P160048-S016

Eversense® E3 Continuous Glucose Monitoring System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 10, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 10, 2022

Approved

Time to decision

498 days

Received Sep 30, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P160048-S016
Device name
Eversense® E3 Continuous Glucose Monitoring System
Applicant location
Germantown, MD
Received
Sep 30, 2020
Decided
Feb 10, 2022
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160048

Device type

Device class
Class III

Every decision under product code QHJ

FDA's approval statement

As written in FDA's record.

Approval for the Eversense® E3 Continuous Glucose Monitoring System for expanding the indications for use and modifying the sensor design to allow use for up to 180 days.

Source documents

Other decisions for Senseonics, Incorporated

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

4 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.